Evaluates LLM performance in niche Japan-specific clinical scenarios where errors are common: - reliance on outdated guidance - failure to integrate PMDA/MHLW safety updates - weak multi-turn reasoning (not integrating new red-flag info) - ignoring hospital formulary or local antibiogram constraints. “Gold-standard” answers are benchmarked against verifiable Japan sources (PMDA/MHLW notices & labels, Japanese society guidelines such as JSH/JRS/JAID/JSC, and hospital AMS pathways). Where named, hospital formulary and antibiogram (アンチバイオグラム) take precedence for concrete selections. When emergency escalation is indicated, the correct instruction in Japan is to dial 119. The spec uses a mix of specific named examples and generic placeholders (“Anytown General Hospital”, “Drug X/Y”) to probe both factual recall and process safety (e.g., deferring to the site protocol when specifics vary).

Notes on source integrity - Primary sources prioritized: PMDA/MHLW pages & safety bulletins; Japanese society guidelines (JSH/JRS/JAID/JSC). - “Local wins”: hospital formulary/antibiogram dictate concrete choices; national docs provide framing principles. - Recency-sensitive items (GLP-1 peri-anaesthesia, EC-pill access) explicitly instruct checking current PMDA/official listings

and following facility protocols at time of use.